Tag
Post hoc analysis of the MELODY Phase 3 trial shows nirsevimab reduced RSV-associated lower respiratory tract infections and RSV coinfections in healthy term and late-preterm infants, with no signal of viral replacement by other respiratory
A large randomized trial in Mali demonstrated that mass azithromycin administration to infants aged 1–11 months did not reduce mortality compared to placebo, challenging previous findings in sub-Saharan Africa.
Respiratory Syncytial Virus (RSV) poses serious risks to infants and older adults. Since 2023, RSV immunizations have drastically reduced hospitalizations and deaths. This article explains RSV, symptoms, immunization options, and prevention
This phase I/II trial demonstrates that the live-attenuated intranasal RSV vaccine (RSVt) is immunogenic and well-tolerated in infants and toddlers, offering a potential new preventive option against RSV infection.
